Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

- New Data Presented at American Society of Clinical Oncology's

Genitourinary Symposium -

SEATTLE and SAN FRANCISCO, Feb. 14 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented data demonstrating the correlation of a measure of the cumulative potency of PROVENGE (sipuleucel-T), an investigational active cellular immunotherapy for hormone-refractory prostate cancer, with overall survival. This is the first time that an association between higher potency of an active immune therapy and increased patient survival has been reported. The correlation appeared to be independent of other important baseline prognostic factors.

The abstract (#21), "Cell Number and CD54 Expression in Sipuleucel-T Correlate with Survival in Metastatic Androgen Independent Prostate Cancer," is being presented at the American Society of Clinical Oncology's 2008 Genitourinary Symposium in San Francisco.

In two Phase 3 trials, D9901 and D9902A, researchers evaluated cumulative product release parameters of PROVENGE, including CD54 upregulation (a measure of product potency defined as the increase of CD54 molecules expressed on Antigen Presenting Cells [APC] after incubation with the PROVENGE Antigen Delivery Cassette(TM)) and the number of total nucleated cells (TNCs) among patients treated with sipuleucel-T (n=146). CD54 is a costimulatory molecule which serves as a marker for APCs. Its expression is increased when APCs become activated and this upregulation of CD54 serves as a potency release assay for PROVENGE.

Results showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... DUBLIN, Calif., April 14, 2011 Carl Zeiss ... microscope system at the 79th Annual Meeting of ... Denver, Colo. Based on the breakthrough OPMI® Pentero ... offers innovative new features and customer benefits such ...
... results from the largest multicenter clinical trial for heart ... International Society for Heart & Lung Transplantation (ISHLT) 31st ... show clinical benefit for the use of Everolimus in ... randomized patients at 67 medical centers spanning 5 continents. ...
Cached Medicine Technology:PENTERO 900: Elevating Excellence in Microsurgery to a New Level 2PENTERO 900: Elevating Excellence in Microsurgery to a New Level 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... to move forward in U.S. courts, Bernstein Liebhard LLP ... elevated metal ion levels to the failure of metal-on-metal ... 2nd issue of The Journal of Bone & Joint ... received unilateral Articular Surface Replacement prostheses at least twelve ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Doylestown Hospital ... a variety of men’s health questions. Paddock tackles ... to men, why women live longer than men, and ... Men's Health Made Simple featured on Doylestown Hospital’s ... a hernia at any age. If you notice pain, ...
(Date:7/12/2014)... Praeclarus Press is excited to ... new resource for women in need of lactation support. ... away from their children. Today’s mothers receive very clear ... but often feel unsupported when it comes to balancing ... evidence-based insights, and written by Nancy Mohrbacher, an international ...
(Date:7/12/2014)... 12, 2014 The largest pure occupational ... pleased to announce that it will be opening its ... facility will join four Atlanta-based Nova Medical Centers’ locations. ... 3209 Deans Bridge Road, and will be open from ... , “With Nova’s treatment philosophy of rapid return-to-work and ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... , The Authority offers patients consumer ... Advisories for improved patient safety , , ... Authority supports "National Patient Safety Day," Saturday, July 25, which is ... an active role in their healthcare. , , ...
... SHENYANG, China, July 24 /PRNewswire-Asia/ -- Neusoft Medical ... Neusoft Corporation,(600718.SH), officially announced that its newly developed Computed,Tomography(CT) ... by,the FDA recently, and is also marked as the ... multi-slice CT scanner was shipped to its U.S.-based customers,recently, ...
... and phosphate content is common, but labeling is not ... -- Additives used to "enhance" uncooked meat and poultry ... disease, researchers say. , Many fresh meat and poultry ... and flavorings that are not required to be listed ...
... , KENILWORTH, N.J., July 24 Schering-Plough ... settlement, subject to Court approval, to resolve litigation seeking to ... other forms of relief. The consolidated class action lawsuits, ... 2009, were filed in U.S. District Court for the District ...
... , DUBLIN, Ohio, July 24 Cardinal Health ... officer (CIO), effective Aug. 3. , , ... enterprise-wide information technology infrastructure and will work to enhance the ... report to George Barrett, who will become chairman and chief ...
... Dialysis Corporation of America (Nasdaq: DCAI ) announced today ... Wednesday August 5, 2009, after the close of the market. The ... second quarter 2009 earnings release the following morning, Thursday, August 6, ... Those interested in participating in the August 6, 2009 ...
Cached Medicine News:Health News:Pennsylvania Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Pennsylvania Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 2Health News:Neusoft Medical's Latest Innovation, NeuViz 16 CT Scanner, Approved by FDA for the U.S. Market 3Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck 2Health News:Cardinal Health Names Patricia Morrison Chief Information Officer 2Health News:Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 2
Introducer Sheath Designed for Vascular Access...
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
Medicine Products: